Ta­laris Ther­a­peu­tics bags an­oth­er $115M to curb im­muno­sup­pres­sion in or­gan trans­plant pa­tients

Just over a year af­ter se­cur­ing a $100 mil­lion Se­ries A round, Ta­laris Ther­a­peu­tics is back with a $115 mil­lion Se­ries B to fu­el its mis­sion of mak­ing or­gan trans­plants safer.

CEO Scott Re­quadt said he’s seen “dra­mat­ic progress” since the Se­ries A. In the last 18 months, the biotech has crossed the Phase III start­ing line with its lead drug, FCR001, in liv­ing donor kid­ney trans­plant re­cip­i­ents. Plus, it “laid the ground­work” for two Phase II stud­ies, he not­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER